Cargando…

Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways

BACK GROUND: Atherosclerosis is the major cause of death. The most common risk factors are hyperlipidemia, diabetes, and other factors like chronic infection and inflammation. OBJECTIVE: This study was undertaken to assess the effect of sitagliptin on atherosclerosis via interfering with inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Majeed, Sahar A, Hadi, Najah R, Al Mudhafar, Ahmed M, Al-Janabi, Hussein A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687767/
https://www.ncbi.nlm.nih.gov/pubmed/26770677
http://dx.doi.org/10.1177/2050312113499912
_version_ 1782406667693981696
author Majeed, Sahar A
Hadi, Najah R
Al Mudhafar, Ahmed M
Al-Janabi, Hussein A
author_facet Majeed, Sahar A
Hadi, Najah R
Al Mudhafar, Ahmed M
Al-Janabi, Hussein A
author_sort Majeed, Sahar A
collection PubMed
description BACK GROUND: Atherosclerosis is the major cause of death. The most common risk factors are hyperlipidemia, diabetes, and other factors like chronic infection and inflammation. OBJECTIVE: This study was undertaken to assess the effect of sitagliptin on atherosclerosis via interfering with inflammatory and oxidative pathways. MATERIALS AND METHODS: A total of 18 local domestic male rabbits were included in this study. The animals were randomly divided into three groups (6 rabbits in each group): Group I normal were fed with chow (oxiod) diet for 12 weeks. Group II were fed with 1% cholesterol enriched diet for 12 weeks. Group III rabbits fed with cholesterol enriched diet for 6 weeks, and then continued on cholesterol enriched diet and treated with sitagliptin 125 mg/kg/day orally for the next 6 weeks. Blood samples were collected at the start of the study, at 6 weeks of the study and then at the end of treatment to measure serum lipids profile, hsCRP and TNFα. At end of the study, the aorta was removed for measurement of MDA, glutathione and, aortic intima-media thickness. RESULTS: Sitagliptin results in a significant reduction (p < 0.05) in serum level of total cholesterol (TC), triglycerides (TG), high sensitive C-reactive protein (hsCRP) and TNFα with a significant increase (p < 0.05) in serum HDL level. There was a significant reduction (p < 0.05) in aortic MDA, in comparison to the untreated control group. Furthermore, sitagliptin causes significant increment (p < 0.05) in aortic GSH in comparison to induced untreated group. Regarding histopathological results, sitagliptin results in a significant reduction (p < 0.05) in atherosclerotic lesions in comparison to the induced untreated group and significant reduction in aortic intima-media thickness (p < 0.05). CONCLUSION: Sitagliptin reduced atherosclerosis progression in hyperlipidemic rabbit via its effect on lipid parameters and interfering with inflammatory and oxidative stress.
format Online
Article
Text
id pubmed-4687767
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-46877672016-01-14 Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways Majeed, Sahar A Hadi, Najah R Al Mudhafar, Ahmed M Al-Janabi, Hussein A SAGE Open Med Original Article BACK GROUND: Atherosclerosis is the major cause of death. The most common risk factors are hyperlipidemia, diabetes, and other factors like chronic infection and inflammation. OBJECTIVE: This study was undertaken to assess the effect of sitagliptin on atherosclerosis via interfering with inflammatory and oxidative pathways. MATERIALS AND METHODS: A total of 18 local domestic male rabbits were included in this study. The animals were randomly divided into three groups (6 rabbits in each group): Group I normal were fed with chow (oxiod) diet for 12 weeks. Group II were fed with 1% cholesterol enriched diet for 12 weeks. Group III rabbits fed with cholesterol enriched diet for 6 weeks, and then continued on cholesterol enriched diet and treated with sitagliptin 125 mg/kg/day orally for the next 6 weeks. Blood samples were collected at the start of the study, at 6 weeks of the study and then at the end of treatment to measure serum lipids profile, hsCRP and TNFα. At end of the study, the aorta was removed for measurement of MDA, glutathione and, aortic intima-media thickness. RESULTS: Sitagliptin results in a significant reduction (p < 0.05) in serum level of total cholesterol (TC), triglycerides (TG), high sensitive C-reactive protein (hsCRP) and TNFα with a significant increase (p < 0.05) in serum HDL level. There was a significant reduction (p < 0.05) in aortic MDA, in comparison to the untreated control group. Furthermore, sitagliptin causes significant increment (p < 0.05) in aortic GSH in comparison to induced untreated group. Regarding histopathological results, sitagliptin results in a significant reduction (p < 0.05) in atherosclerotic lesions in comparison to the induced untreated group and significant reduction in aortic intima-media thickness (p < 0.05). CONCLUSION: Sitagliptin reduced atherosclerosis progression in hyperlipidemic rabbit via its effect on lipid parameters and interfering with inflammatory and oxidative stress. SAGE Publications 2013-09-12 /pmc/articles/PMC4687767/ /pubmed/26770677 http://dx.doi.org/10.1177/2050312113499912 Text en © The Author(s) 2013 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).
spellingShingle Original Article
Majeed, Sahar A
Hadi, Najah R
Al Mudhafar, Ahmed M
Al-Janabi, Hussein A
Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title_full Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title_fullStr Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title_full_unstemmed Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title_short Sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
title_sort sitagliptin ameliorates the progression of atherosclerosis via down regulation of the inflammatory and oxidative pathways
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687767/
https://www.ncbi.nlm.nih.gov/pubmed/26770677
http://dx.doi.org/10.1177/2050312113499912
work_keys_str_mv AT majeedsahara sitagliptinamelioratestheprogressionofatherosclerosisviadownregulationoftheinflammatoryandoxidativepathways
AT hadinajahr sitagliptinamelioratestheprogressionofatherosclerosisviadownregulationoftheinflammatoryandoxidativepathways
AT almudhafarahmedm sitagliptinamelioratestheprogressionofatherosclerosisviadownregulationoftheinflammatoryandoxidativepathways
AT aljanabihusseina sitagliptinamelioratestheprogressionofatherosclerosisviadownregulationoftheinflammatoryandoxidativepathways